https://ntp.niehs.nih.gov/go/40444

Transgenic model evaluation II (Aspartame): Target Organs and Levels of Evidence for GMM-01

Toxicology Studies of Aspartame (CASRN 22839-47-0) in Genetically Modified (FVB Tg.AC Hemizygous) and B6.129-Cdkm2atn1Rdp (N2) Deficient Mice and Carcinogenicity Studies of Aspartame in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Feed Studies)

Chemical (Study Title)
CASRN 		Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Transgenic model evaluation II (Aspartame)
22839-47-0 		05/22/2003 Artificial sweetener to be tested using various strains of transgenic animal models. Dosed-Feed
0, 3,125, 6,250, 12,500, 25,000 or 50,000 ppm; 15 animals/sex/dose 		BioReliance, Inc

Levels of evidence information for Feed and Genetic Toxicology Studies of Aspartame in Tg.AC Hemizygous Mice
  Male Tg.AC Hemizygous Mice Female Tg.AC Hemizygous Mice
  39 Weeks 39 Weeks
Neoplastic Lesions None None
Non-Neoplastic Lesions None None

Levels of evidence information for Feed and Genetic Toxicology Studies of Aspartame in p53 Haploinsufficient Mice
  Male p53 Haploinsufficient Mice Female p53 Haploinsufficient Mice
  39 Weeks 39 Weeks
Levels of Evidence No Evidence No Evidence
Neoplastic Lesions None None
Non-Neoplastic Lesions None None

Levels of evidence information for Feed and Genetic Toxicology Studies of Aspartame in Cdkn2a Deficient Mice
  Male Cdkn2a Deficient Mice Female Cdkn2a Deficient Mice
  39 Weeks 39 Weeks
Levels of Evidence No Evidence No Evidence
Neoplastic Lesions None None
Non-Neoplastic Lesions Liver: hepatocyte, cytoplasmic periportal vacuolization None